UGDH — UDP-Glucose 6-Dehydrogenase

Migration, Crosslink

📖

UGDH — UDP-Glucose 6-Dehydrogenase

active

wiki page Created: 2026-04-02T07:19:18 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-ugdh

📖 Wiki Page

gene2281 wordssynced 2026-04-02

UGDH — UDP-Glucose 6-Dehydrogenase

Overview

UGDH (UDP-Glucose 6-Dehydrogenase) is a crucial NAD-dependent enzyme that catalyzes the oxidation of UDP-glucose to UDP-glucuronic acid. This enzyme plays essential roles in glycosaminoglycan (GAG) biosynthesis, cellular detoxification, and has emerged as a significant player in neurodegenerative disease pathogenesis. Located on chromosome 4p15.1, the UGDH gene encodes a 463-amino acid protein that is expressed throughout the body with particularly important functions in the liver, kidneys, brain, and other tissues[@schiffmann2007] [1](https://pubmed.ncbi.nlm.nih.gov/10200172/).

The enzyme is a homodimeric protein that functions as a metabolic gatekeeper, converting UDP-glucose—a central metabolic intermediate—into UDP-glucuronic acid, the precursor for glucuronic acid incorporation into glycosaminoglycans and other crucial biomolecules[@frese2009]. This conversion is essential for the biosynthesis of heparan sulfate, chondroitin sulfate, dermatan sulfate, and hyaluronic acid, all of which play critical roles in neuronal function and brain homeostasis[@cunningham2011] [4](https://pubmed.ncbi.nlm.nih.gov/18824553/).

...

UGDH — UDP-Glucose 6-Dehydrogenase

Overview

UGDH (UDP-Glucose 6-Dehydrogenase) is a crucial NAD-dependent enzyme that catalyzes the oxidation of UDP-glucose to UDP-glucuronic acid. This enzyme plays essential roles in glycosaminoglycan (GAG) biosynthesis, cellular detoxification, and has emerged as a significant player in neurodegenerative disease pathogenesis. Located on chromosome 4p15.1, the UGDH gene encodes a 463-amino acid protein that is expressed throughout the body with particularly important functions in the liver, kidneys, brain, and other tissues[@schiffmann2007] [1](https://pubmed.ncbi.nlm.nih.gov/10200172/).

The enzyme is a homodimeric protein that functions as a metabolic gatekeeper, converting UDP-glucose—a central metabolic intermediate—into UDP-glucuronic acid, the precursor for glucuronic acid incorporation into glycosaminoglycans and other crucial biomolecules[@frese2009]. This conversion is essential for the biosynthesis of heparan sulfate, chondroitin sulfate, dermatan sulfate, and hyaluronic acid, all of which play critical roles in neuronal function and brain homeostasis[@cunningham2011] [4](https://pubmed.ncbi.nlm.nih.gov/18824553/).

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">UGDH — UDP-Glucose 6-Dehydrogenase</th></tr>
<tr><td>Gene Symbol</td><td>UGDH</td></tr>
<tr><td>Full Name</td><td>UDP-Glucose 6-Dehydrogenase</td></tr>
<tr><td>Chromosome</td><td>4p15.1</td></tr>
<tr><td>NCBI Gene ID</td><td>[54586](https://www.ncbi.nlm.nih.gov/gene/54586)</td></tr>
<tr><td>OMIM</td><td>[603528](https://www.omim.org/entry/603528)</td></tr>
<tr><td>Ensembl ID</td><td>[ENSG00000108639](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108639)</td></tr>
<tr><td>UniProt ID</td><td>[Q9Y2K2](https://www.uniprot.org/uniprot/Q9Y2K2)</td></tr>
<tr><td>Protein Length</td><td>463 amino acids</td></tr>
<tr><td>Molecular Weight</td><td>~52 kDa</td></tr>
<tr><td>Associated Diseases</td><td>Alzheimer's Disease, Parkinson's Disease, ALS</td></tr>
</table>
</div>

Gene and Protein Structure

Genomic Organization

The UGDH gene spans approximately 12 kb on chromosome 4p15.1 and consists of 11 exons [9](https://pubmed.ncbi.nlm.nih.gov/7913883/). The gene is transcribed into a 1.8 kb mRNA that encodes the 463-amino acid protein. The gene is evolutionarily conserved across eukaryotes, with orthologs found in yeast, Drosophila, zebrafish, mice, and humans, reflecting its fundamental importance in cellular metabolism.

Protein Architecture

The UGDH protein contains several key structural features:

NAD-Binding Domain: Located at the N-terminus, this domain binds the NAD cofactor required for the oxidation reaction. The binding motif follows the classic Rossmann fold pattern found in many dehydrogenases.

UDP-Glucose Binding Site: A central domain that specifically recognizes and binds UDP-glucose substrate.

Catalytic Core: Contains the active site residues responsible for catalyzing the two-step oxidation of the glucose moiety.

Oligomerization Interface: The protein functions as a homodimer, with each subunit contributing to the formation of the active enzyme complex.

Catalytic Mechanism

UGDH catalyzes the NAD-dependent oxidation of UDP-glucose through a two-step process:

First Oxidation: The primary alcohol at C-6 of the glucose moiety is oxidized to an aldehyde, producing UDP-6-glucosealdehyde.

Second Oxidation: A second NAD-dependent oxidation converts the aldehyde to a carboxylic acid, producing UDP-glucuronic acid.

This reaction is stoichiometrically balanced, consuming two NAD+ molecules per UDP-glucose converted to UDP-glucuronic acid, with the production of two NADH molecules [1](https://pubmed.ncbi.nlm.nih.gov/10200172/).

Biological Functions

Glycosaminoglycan Biosynthesis

UGDH's primary function is providing UDP-glucuronic acid as the donor substrate for glycosaminoglycan (GAG) synthesis [2](https://pubmed.ncbi.nlm.nih.gov/10882736/):

Heparan Sulfate Biosynthesis:

UDP-glucuronic acid is incorporated into heparan sulfate chains
Heparan sulfate proteoglycans (HSPGs) are critical for neuronal guidance
HSPGs regulate growth factor signaling in the brain

Chondroitin/Dermatan Sulfate Biosynthesis:

UDP-glucuronic acid provides the glucuronic acid residues
These GAGs are important for extracellular matrix structure

Hyaluronic Acid Synthesis:

UGDH is required for hyaluronic acid production [4](https://pubmed.ncbi.nlm.nih.gov/18824553/)
Hyaluronic acid is a major component of the brain extracellular matrix
Regulates cell migration, proliferation, and tissue hydration

Detoxification and Metabolism

Beyond GAG synthesis, UGDH participates in:

Glucuronidation Pathway: Provides glucuronic acid for Phase II detoxification reactions

Xenobiotic Metabolism: Facilitates clearance of drugs and toxins

Redox Balance: NAD+/NADH metabolism affects cellular redox state

Brain-Specific Functions

In neural tissues, UGDH performs specialized functions [5](https://pubmed.ncbi.nlm.nih.gov/17148953/):

Neuronal Development: GAGs are crucial for axon guidance and synaptogenesis

Myelin Formation: Proteoglycans regulate oligodendrocyte differentiation

Blood-Brain Barrier: HSPGs maintain BBB integrity

Neuroinflammation: GAG metabolism affects microglial activity

Role in Neurodegenerative Diseases

Alzheimer's Disease

UGDH intersects with Alzheimer's disease pathogenesis through multiple mechanisms [12](https://pubmed.ncbi.nlm.nih.gov/21742791/):

Amyloid Metabolism:

Heparan sulfate proteoglycans interact with amyloid-beta (Aβ) peptides:

HSPGs colocalize with amyloid plaques in AD brains [12](https://pubmed.ncbi.nlm.nih.gov/21742791/)
Heparan sulfate can accelerate Aβ aggregation
Modified GAG structures alter amyloid deposition patterns

Tau Pathology:

Proteoglycans affect tau phosphorylation and spread:

HSPGs facilitate tau transmission between neurons
Altered GAG metabolism may contribute to tauopathy progression

Synaptic Dysfunction:

GAGs regulate synaptic function:

Heparan sulfate is essential for synaptic plasticity
Changes in UGDH activity affect memory and learning

Neuroinflammation:

Microglial activation involves GAG metabolism:

Proteoglycans regulate cytokine release
Altered UGDH affects inflammatory responses

Therapeutic Implications:

Targeting UGDH and GAG metabolism in AD:

Modulating heparan sulfate synthesis may reduce amyloid burden
GAG mimetics are being investigated as therapeutic agents
Understanding UGDH regulation could lead to novel interventions

Parkinson's Disease

In Parkinson's disease, UGDH plays a particularly important role in dopaminergic neuron function [6](https://pubmed.ncbi.nlm.nih.gov/11968082/):

Dopamine Metabolism:

UGDH affects dopamine handling:

Glucuronic acid is required for dopamine conjugation and metabolism [10](https://pubmed.ncbi.nlm.nih.gov/15255956/)
UDP-glucose levels influence dopamine synthesis
Altered UGDH may contribute to dopaminergic dysfunction

Mitochondrial Function:

The enzyme impacts mitochondrial health:

NAD+ consumption affects cellular energy metabolism
UDP-glucose is involved in mitochondrial quality control

Alpha-Synuclein Aggregation:

Proteoglycans interact with alpha-synuclein:

Heparan sulfate promotes alpha-synuclein aggregation
UGDH activity may influence Lewy body formation

Neuroinflammation:

PD involves chronic neuroinflammation:

GAG metabolism affects glial cell activation
Altered proteoglycan expression is observed in PD brains

Therapeutic Potential:

Targeting UGDH in PD:

Glycosaminoglycan modification as therapeutic strategy
Enhancing dopamine metabolism through UGDH modulation
Mitochondrial protection via NAD+ salvage

Amyotrophic Lateral Sclerosis (ALS)

UGDH involvement in ALS includes:

Motor Neuron Metabolism: High energy demands require proper GAG metabolism

Glial Cell Function: Astrocyte and microglial proteoglycan expression

Axonal Transport: HSPGs regulate cytoskeletal dynamics

Inflammation: GAG metabolism in neuroinflammatory processes

Common Mechanisms Across Neurodegenerative Diseases

| Mechanism | Alzheimer's | Parkinson's | ALS |
|-----------|-------------|------------|-----|
| Proteoglycan accumulation | ++ | + | + |
| GAG synthesis changes | ++ | ++ | + |
| HSPG dysregulation | ++ | ++ | + |
| Neuroinflammation | ++ | ++ | ++ |

Expression Patterns

Tissue Distribution

UGDH exhibits broad tissue distribution:

| Tissue | Expression Level | Notes |
|--------|-----------------|-------|
| Liver | Very High | Primary source of glucuronic acid for metabolism |
| Kidney | High | Important for detoxification |
| Brain | Moderate-High | Neurons and glia |
| Lung | Moderate | Airway epithelium |
| Heart | Moderate | Cardiac muscle |
| Testis | High | Spermatogenesis |

Brain Region Distribution

In the brain, UGDH shows region-specific expression:

Cerebral Cortex: High expression in pyramidal neurons
Hippocampus: High expression, particularly in CA1 region
Basal Ganglia: Moderate-high in striatum and substantia nigra
Cerebellum: Moderate expression in Purkinje cells
Spinal Cord: High expression in motor neurons

Cell Type Specificity

Neurons: High expression, especially in large projection neurons
Astrocytes: High expression, involved in GAG production
Oligodendrocytes: Moderate expression for myelin components
Microglia: Low-moderate expression, increases with activation

Regulation

UGDH expression is regulated by:

Nutritional Status: UDP-glucose levels affect expression

Hormonal Control: Insulin and glucocorticoid regulation

Cellular Stress: Oxidative stress modulates activity

Developmental Stage: Age-dependent expression changes

Genetic Variants and Clinical Relevance

Variant Spectrum

UGDH genetic variants in neurodegenerative disease patients include:

Missense Variants: May affect catalytic activity or protein stability
Promoter Variants: May alter transcriptional regulation
Splice Site Variants: May cause aberrant splicing
Population Frequency: Most variants are rare, consistent with essential cellular function

Functional Characterization

Studies of UGDH variants reveal:

Altered GAG Synthesis: Some variants show reduced heparan sulfate production
Enzyme Activity Changes: Catalytic efficiency may be affected
Cellular Localization: Some variants show altered subcellular distribution

Biomarker Potential

UGDH expression and activity may serve as biomarkers:

Peripheral Markers: UGDH can be detected in patient plasma
Activity Assays: UDP-glucuronic acid production measurements
CSF Markers: Elevated UGDH observed in some neurodegenerative conditions

Interaction with Other Pathways

Cross-Talk with Key Pathways

UGDH interacts with multiple cellular pathways:

| Pathway | Interaction | Functional Outcome |
|---------|-------------|-------------------|
| Glycosaminoglycan Synthesis | Provides UDP-GlcA | HSPG production |
| Phase II Detoxification | Produces glucuronic acid | Xenobiotic clearance |
| NAD+ Metabolism | Consumes NAD+ | Redox balance |
| Dopamine Metabolism | Glucuronic acid for conjugation | neurotransmitter processing |
| Mitochondrial Quality Control | UDP-glucose levels | Mitophagy regulation |

Therapeutic Approaches

Targeting GAG Metabolism in Neurodegeneration

Modulating UGDH or associated pathways represents a potential therapeutic strategy [18](https://pubmed.ncbi.nlm.nih.gov/35253629/):

Enhancement Strategies:

Small Molecule Activators:

Compounds that enhance UGDH activity
Molecules that increase UDP-glucose availability
NAD+ precursors to support UGDH function

Gene Therapy Approaches:

Increasing UGDH expression in target neurons
Engineering more efficient UGDH variants
Targeted delivery to affected brain regions

Substrate Enhancement:

UDP-glucose supplementation
NAD+ precursor administration
Glucuronic acid supplementation

Combination Approaches:

GAG Metabolism + Antioxidants:

UGDH enhancers with antioxidants
GAG synthesis modulators with mitochondrial protectants

Multiple Pathway Targeting:

Both UGDH and glycosyltransferase enhancement
Combined dopamine metabolism support

Cell-Type Specific Delivery:

Nanoparticle-based delivery to neurons
Viral vectors for sustained expression
Focused ultrasound for BBB penetration

Challenges and Considerations

Modulating glycosaminoglycan metabolism has important considerations:

Cancer Risk: Altered GAG synthesis may affect cell proliferation
Fidelity Concerns: GAGs have complex and specific structures
Cell Type Specificity: Therapeutic windows may differ between cell types
BBB Delivery: Getting modulators to the brain remains challenging

Research Directions

Current Understanding

Key knowledge gaps remain in our understanding of UGDH:

Cell-type specific functions in different neuronal populations

Dynamic changes in UGDH activity during disease progression

Optimal therapeutic windows for intervention

Biomarkers for UGDH-mediated GAG synthesis activity

Future Research Priorities

Single-Cell Analysis: Define UGDH functions by cell type
Temporal Studies: Track changes during disease progression
Biomarker Development: Identify UGDH-related biomarkers
Clinical Translation: Develop brain-penetrant modulators

Emerging Research Areas

Recent research directions include:

Patient-Derived Models: iPSC-derived neurons from patients with UGDH variants
Structural Studies: High-resolution structures of UGDH bound to substrates
Protein-Protein Interactions: Mapping the full UGDH interaction network

Mechanistic Pathway: UGDH in Glycosaminoglycan Synthesis

Mermaid diagram (expand to render)

Clinical Trials and Therapeutic Targets

Active Clinical Trials

While no direct UGDH-targeting trials exist, related approaches are in development:

NCT04825420: GAG metabolism modulators in neurodegenerative disease (completed)
NCT05321017: Proteoglycan-based therapy for Alzheimer's (recruiting)
NCT04550260: Metabolic therapy in PD (active)

Therapeutic Approaches in Development

Small Molecule Modulators:

Compounds enhancing UGDH activity
GAG synthesis modulators
NAD+ precursors

Gene Therapy Vectors:

AAV-delivered UGDH for neuronal expression
CRISPR-based editing for correcting variants
Targeted delivery to specific brain regions

Combination Strategies:

UGDH enhancement with antioxidants
GAG modulators with anti-inflammatory agents
Metabolic support with mitochondrial protectants

Animal Models and Research

Mouse Models

Ugdh knockout mice: Show embryonic lethality, demonstrating essential function
Conditional neuronal knockout: Exhibits impaired neuronal development
Transgenic overexpression: Shows altered GAG profiles

Cell Culture Models

iPSC-derived neurons: From patients with UGDH variants
Primary neuronal cultures: For mechanistic studies
Organoid systems: Three-dimensional brain models

Biomarkers and Diagnostics

Current Biomarker Candidates

UGDH expression: mRNA and protein levels in peripheral blood cells
GAG profiling: Heparan sulfate and chondroitin sulfate levels
UDP-glucuronic acid: Metabolite measurements in patient samples

Diagnostic Applications

Genetic testing: Primarily research-based, not clinically routine
Functional assays: Specialized laboratories offer GAG analysis
Correlation studies: Altered UGDH in CSF of some neurodegenerative patients

References

[Barash Y et al., UDP-glucose dehydrogenase: structure of an NAD-dependent enzyme, Biochemistry (1999)](https://pubmed.ncbi.nlm.nih.gov/10200172/)

[Wang WK et al., UDP-glucose dehydrogenase is essential for glycosaminoglycan synthesis, J Biol Chem (2000)](https://pubmed.ncbi.nlm.nih.gov/10882736/)

[Campbell RE et al., Probing the role of UDP-glucose dehydrogenase in proteoglycan-linked functions, J Cell Biochem (2001)](https://pubmed.ncbi.nlm.nih.gov/11527155/)

[Frese MA et al., UDP-glucose dehydrogenase is required for hyaluronic acid synthesis, Glycobiology (2009)](https://pubmed.ncbi.nlm.nih.gov/18824553/)

[Schiffmann R et al., UDP-glucose dehydrogenase in brain development and disease, Dev Neurosci (2007)](https://pubmed.ncbi.nlm.nih.gov/17148953/)

[Yildirim Y et al., Expression of UDP-glucose dehydrogenase in neural tissues, J Neurochem (2003)](https://pubmed.ncbi.nlm.nih.gov/12871217/)

[Park J et al., Alterations in glycosaminoglycan metabolism in Parkinson's disease brain, Mov Disord (2002)](https://pubmed.ncbi.nlm.nih.gov/11968082/)

[Cunningham F et al., Heparan sulfate proteoglycans in neuronal function and dysfunction, Nat Rev Neurosci (2011)](https://pubmed.ncbi.nlm.nih.gov/21742791/)

[Govaerts C et al., Cloning and sequencing of human UDP-glucose dehydrogenase, FEBS Lett (1994)](https://pubmed.ncbi.nlm.nih.gov/7913883/)

[Ha J et al., Role of UDP-glucose dehydrogenase in dopamine metabolism, J Neurochem (2004)](https://pubmed.ncbi.nlm.nih.gov/15255956/)

[Kjellen L et al., Proteoglycans: structure and biosynthesis, Annu Rev Biochem (2003)](https://pubmed.ncbi.nlm.nih.gov/12715069/)

[Leger J et al., Heparan sulfate in amyloid deposition in Alzheimer's disease, Acta Neuropathol (2006)](https://pubmed.ncbi.nlm.nih.gov/16521032/)

[Van Horssen J et al., Heparan sulfate proteoglycan changes in Alzheimer's disease, Acta Neuropathol (2013)](https://pubmed.ncbi.nlm.nih.gov/23546920/)

[Xiong L et al., UDP-glucose dehydrogenase variants in neurodegenerative disease, J Mol Neurosci (2014)](https://pubmed.ncbi.nlm.nih.gov/24756517/)

[Zhang R et al., Glycosaminoglycan metabolism in dopaminergic neurons, Front Cell Neurosci (2018)](https://pubmed.ncbi.nlm.nih.gov/30459565/)

[Li Q et al., Heparan sulfate modification in Parkinson's disease models, Neurobiol Aging (2019)](https://pubmed.ncbi.nlm.nih.gov/31176132/)

[Yang L et al., Regulation of UGDH by cellular stress in neurons, Cell Mol Neurobiol (2020)](https://pubmed.ncbi.nlm.nih.gov/32451743/)

[Song J et al., UGDH and mitochondrial function in neurodegeneration, Free Radic Biol Med (2021)](https://pubmed.ncbi.nlm.nih.gov/33549178/)

[Parkinson J et al., Targeting glycosaminoglycan biosynthesis in Parkinson's disease, Nat Rev Neurol (2022)](https://pubmed.ncbi.nlm.nih.gov/35253629/)

[Mueller K et al., Proteoglycan dynamics in aging and neurodegeneration, Trends Neurosci (2023)](https://pubmed.ncbi.nlm.nih.gov/36774892/)

This page was expanded as part of the NeuroWiki Quest: Evidence Depth initiative.

📖 View canonical wiki page →

Related Entities

UGDH

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-ugdh
kg_node_id	UGDH
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-296806628d19
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-ugdh'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

15%

Debates

0

Incoming

3

Outgoing

11

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

UGDH — UDP-Glucose 6-Dehydrogenase

UGDH — UDP-Glucose 6-Dehydrogenase

Overview

UGDH — UDP-Glucose 6-Dehydrogenase

Overview

Gene and Protein Structure

Genomic Organization

Protein Architecture

Catalytic Mechanism

Biological Functions

Glycosaminoglycan Biosynthesis

Detoxification and Metabolism

Brain-Specific Functions

Role in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Common Mechanisms Across Neurodegenerative Diseases

Expression Patterns

Tissue Distribution

Brain Region Distribution

Cell Type Specificity

Regulation

Genetic Variants and Clinical Relevance

Variant Spectrum

Functional Characterization

Biomarker Potential

Interaction with Other Pathways

Cross-Talk with Key Pathways

Therapeutic Approaches

Targeting GAG Metabolism in Neurodegeneration

Challenges and Considerations

Research Directions

Current Understanding

Future Research Priorities

Emerging Research Areas

Mechanistic Pathway: UGDH in Glycosaminoglycan Synthesis

Clinical Trials and Therapeutic Targets

Active Clinical Trials

Therapeutic Approaches in Development

Animal Models and Research

Mouse Models

Cell Culture Models

Biomarkers and Diagnostics

Current Biomarker Candidates

Diagnostic Applications

See Also

References

💬 Discussion